Claims
- 1. A method for alleviating cell damage to the eye in a subject having an ophthalmic inflammatory disease or condition, comprising administering an eye drop comprising an effective amount of a drug that selectively inhibits cyclooxygenase-2 to said subject.
- 2. The method of claim 1, wherein said drug that selectively inhibits cyclooxygenase-2 is etodolac.
- 3. The method of claim 2, wherein the concentration of etodolac ranges from 0.5 to 5%.
- 4. The method of claim 1, wherein the drug that selectively inhibits cyclooxygenase-2 is N-(2-(cyclohexyloxy)-4-nitrophenyl) methane-sulfonamide (NS-398).
- 5. The method of claim 4, wherein the concentration of the N-(2-(cyclohexyloxy)-4-nitrophenyl)methane-sulfonamide (NS-398) ranges from 0.5% to 5%.
- 6. The method of claim 1, wherein the drug the selectively inhibits cyclooxygease-2 is meloxicam.
- 7. The method of claim 6, wherein the concentration of meloxicam ranges from 0.1% to 1%.
Priority Claims (2)
Number |
Date |
Country |
Kind |
10-150788 |
May 1998 |
JP |
|
11-058173 |
Mar 1999 |
JP |
|
Parent Case Info
This application is a continuation of PCT/JP99/02522, filed May, 14, 1999.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
5990148 |
Isakson et al. |
Nov 1999 |
A |
Continuations (1)
|
Number |
Date |
Country |
Parent |
PCT/JP99/02522 |
May 1999 |
US |
Child |
09/712172 |
|
US |